Foundayo vs Ozempic: New Pill vs Proven Injection
Ozempic has been the dominant GLP-1 for years. Now Foundayo enters as a cheaper, oral alternative. Ozempic is FDA-approved for diabetes (widely used off-label for weight loss), while Foundayo is approved specifically for weight management. Here's the full comparison.
Ready to act? Oral GLP-1 options from $99/mo
MEDVi offers GLP-1 tablets and injectables — a licensed provider helps you choose.
The Key Differences
These are fundamentally different drugs despite both being GLP-1 medications:
- Different molecules: Ozempic is semaglutide (a peptide); Foundayo is orforglipron (a small molecule, non-peptide)
- Different molecule types: Ozempic is a peptide full GLP-1 agonist; Foundayo is a non-peptide small molecule GLP-1 receptor agonist
- Different delivery: Weekly injection vs daily pill
- Different FDA indications: Ozempic is for diabetes; Foundayo is for weight management
Why this matters: If you're using Ozempic off-label for weight loss and it's working, there may not be a strong reason to switch — unless cost, convenience, or injection fatigue is an issue. If you do decide to switch, see our complete Ozempic to Foundayo switching guide with dose mapping and timeline.
Cost: Foundayo Is Dramatically Cheaper
This is where the comparison gets stark:
- Ozempic: ~$936/month list price. One price for all doses.
- Foundayo: $149/month (starting) to $349/month (max). Lilly specifically priced it to undercut injectables.
At the starting dose, Foundayo is 84% cheaper than Ozempic. Even at the highest dose, it's still 63% cheaper. For uninsured or underinsured patients, this price difference is life-changing. See our guide to GLP-1s without insurance.
With savings cards, both drop to $25/month — but savings cards have eligibility requirements and don't work with Medicare or Medicaid. The new Medicare GLP-1 Bridge Program (July 2026) will expand access.
Weight Loss Results
Ozempic at 2.0mg: In STEP-equivalent analyses, semaglutide 2.0mg shows approximately 15% weight loss. Note: Ozempic's max approved dose is 2.0mg (vs Wegovy's 2.4mg).
Foundayo at highest dose: 12.4% weight loss in ATTAIN-1 (completers at 36mg trial dose) / 11.2% treatment regimen (all randomized).
Ozempic has a modest efficacy advantage (~3 percentage points), but Foundayo’s results are clinically meaningful — roughly 27 lbs average weight loss at the highest dose. See our Foundayo weight loss timeline for what to expect month by month.
A head-to-head comparison was published in The Lancet (the ATTAIN-3 trial, Lilly-funded): In type 2 diabetes patients, orforglipron outperformed oral semaglutide (Rybelsus 7-14mg) on weight loss and A1C reduction. However, Novo Nordisk pointed out this used their lower diabetes dose, not the higher weight management dose.
Compare Your Personalized Switch Plan
Frequently Asked Questions
Sources
- ATTAIN-1 Phase 3 Trial — orforglipron weight loss data
- SUSTAIN / STEP Trial Programs — semaglutide data
- ATTAIN-3 (Lancet, 2026) — orforglipron vs oral semaglutide head-to-head
- Foundayo FDA Prescribing Information
- Ozempic FDA Prescribing Information
Don't miss price changes
GLP-1 prices are changing — stay ahead
Foundayo prices may increase — get alerts before they do. Track price drops, shortages, and new switching guidance without checking back manually.
- Price increase warnings before they hit
- Savings card and coupon alerts
- New switching guidance and availability updates
No spam. Unsubscribe anytime. We never share your email.
Compare GLP-1 Providers
Get a prescription in as little as 24 hours — no in-person visit required.
GLP-1 weight loss program — take a 60-second quiz to see if you qualify. Compounded semaglutide and tirzepatide from $99/month with provider support.
Starts at $99/mo — one of the most affordable GLP-1 programs
MedSwitcher may earn a commission from some providers. Full disclosure. This does not affect our recommendations.
Recommended Products
Supplies and tools commonly used by GLP-1 patients during their treatment journey.
As an Amazon Associate, MedSwitcher earns from qualifying purchases. Product links do not affect our clinical recommendations.